| Revenue growth | 310% YoY growth in revenue from operations to ₹408.4 Cr. |
|---|---|
| Margins | EBITDA margin at 25.2% (Q1 FY27) vs -14.4% (Q1 FY26). |
| Order book | ₹57 crore in deferred Gulf export orders recognized in Q1 FY27. |
| Demand visibility | Strong growth led by test-kit consumption across 12,500+ installed devices. |
| Management confidence | High; emphasizing milestone listing year and volume-led scale-up readiness. |
Growth
Q1 FY27 Revenue rose 310% YoY to ₹408.4 Cr; PAT turned positive at ₹52.7 Cr vs ₹(23.9) Cr loss.
Outlook
Capex underway for Bengaluru R&D and automation; pipeline of 34 additional assays across 22 diseases remains on track.
Risks
Non-linear revenue profile with performance varying across quarters; geopolitical issues in the Gulf caused order deferrals.
Investor Presentation filed with NSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,246.00
- Market cap
- ₹14,359 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- Promoter holding
- 41.29%
- FII holding
- 1.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Other Announcement
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
- Execution
- 12 months
Molbio Diagnostics Board Meeting Outcome
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
- Execution
- Financial Year 2026-27
Molbio Diagnostics Capital Structure Change
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio Diagnostics Earnings Call Transcript: Key Takeaways
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
- Call
- Guides 25% growth
Molbio Diagnostics Other Announcement
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics Results Update
Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr and PAT of ₹52.74 Cr, a swing from prior-year losses. Growth was driven by Truenat test-kit volume and deferred Gulf export orders.